31 results
To investigate the influence of platform-switched implant-abutment connections (smaller diameter abutment on wider diameter implant) of short implants (8.5 mm in length) on marginal peri-implant bone levels and clinical variables.
To investigate the influence of short implants (6 mm in length) on marginal peri-implant bone levels, clinical variables and patient satisfaction.
The primary objective of this study is to investigate the improvement of masticatory function of implant-supported RPD treatment in free-ending, bilateral mandibular partial edentulism. The secondary objectives include patient satisfaction (OHIP14…
To perform a pilot study to determine the feasibility of conducting a two-arm phase I trial and to determine the recommended dose level for phase II (RP2D) study and assess the safety of the combination olaparib and melphalan in patients with…
The Primary objective is to assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg/ valsartan 320 mg in patients with essential hypertension (msDBP > 90 mmHg and < 110 mmHg.
Thel aim of this project is to analyse hybrid implants placed in de posterior mandible of periodontally compromised patients and to compare the treatment outcome of either moderate rough or hybrid implants.
Part 1: Determine the Recommended Phase II Dose
The current trial aims to asses the safety of this combination in a phase I trial with olaparib dose escalation during two cycles of 177Lu-DOTATATE in salvage setting in patients with advanced GEP NET, progressive after initial PRRT.
Primary: To determine whether the outcome of the RAD51 assay (HR proficient or HR deficient) correlates with objective response rate (RR) of olaparib, in patients with recurrent high grade epithelial ovarian cancer.Secondary:• Compare the…
Primary objective To investigate the safety and tolerability of CCS1477 as monotherapy and in combination.
This study is evaluating the preliminary efficacy of UV1-olaparib-durvalumab combination against both olaparib as monotherapy and olaparib-durvalumab combination in maintenance after platinum combination therapy for BRCAwt patients with relapsed…
Part APrimary objective1. To determine the equivalence of the Area-Under-the-Curve (AUC) of the reduced, boosted dose of olaparib and the regular dose.Secondary objectives1. To determine whether boosting reduces the inter- and intrapatient PK…
To determine the efficacy of olaparib versus placebo on progression free survival (PFS).
1) To compare pembrolizumab plus olaparib to abiraterone acetate or enzalutamide with respect to overall survival (OS)2) To compare pembrolizumab plus olaparib to abiraterone acetate or enzalutamide with respect to radiographic progression-free…
Primary Objectives• To describe the anti-tumor activity and toxicity of commercially available, targeted anti-cancer drugs used for treatment of patients with an advanced solid tumor, multiple myeloma or non-Hodgkin lymphoma that harbours a genomic…
The aim of this study to evaluate the clinical performance of short implants (4 mm in length) in the resorbed posterior mandibular region of partially edentulous patients that will be restored with a single crown.
• To evaluate the effect of olaparib on exposure to anastrozole by determination of steady-state exposure to anastrozole in the presence and absence of steady-state exposure to olaparib• To evaluate the effect of anastrozole on exposure to olaparib…
Primary objective: to define the maximal tolerated dose (MTD) of Olaparib in combination with high dose radiotherapy with and without daily dose cisplatin in locally advanced non-small cell lung carcinoma.
To investigate the influence of different implant neck designs on marginal peri-implant bone levels and clinical variables.
The aim of the study is comparison of two and four dental implants supporting an overdenture in the upper jaw for patients who experience problems with retention and stability of the upper denture.